References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of oestrogen plus progestagen in healthy postmenopausal women. JAMA 2002;288:321–33
- Million Women Study Collaborator. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419–27
- Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014;79:287–91
- Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the women’s health initiative randomized placebo-controlled trial. Lancet Oncol 2012;13:476–86
- Stefanick ML, Anderson GL, Margolis KL, et al. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
- LaCroix AZ, Chlebowski RT, Manson JE, et al. WHI Investigators. Health out-comes after stopping conjugated equine estrogens among postmenopausalwomen with prior. JAMA 2011;305:1305–14
- Schierbeck L. Primary prevention of cardiovascular disease with hormone replacement therapy. Climacteric 2015;18:1–6
- Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
- Hodis HN, Mack WJ. A “window of opportunity”: the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 2011;1379:244–52
- Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291:1701–12
- Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011;14:633–6
- Eisenberger A, Westhoff C. Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol 2014;142:76–82
- Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
- Petrone AB, Simpkins JW, Barr TL. 17β-estradiol and inflammation: implications for ischemic stroke. Aging Dis 2014;5:340–5
- Gambrell RD Jr. The prevention of endometrial cancer in postmenopausal women with progestogens. Maturitas 1978;1:107–12
- Sarrel PM. How progestagens compromise the cardioprotective effects of oestrogens (Editorial). Menopause 1995;2:187–90
- Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963–7
- Wildemeersch D, Janssens D, Weyers S. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination? Maturitas 2005;51:207–14
- Wildemeersch D, Pylyser K, De Wever N, et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas 2007;57:205–9
- Hendrickson MR , Kempson RL. Surgical pathology of the uterine corpus. In: Saunders WB, ed. Major problems in pathology. Philadelphia: Saunders. Vol 12. 1980;99–158
- Kurman RJ. Blaustein’s pathology of the female genital tract. In: Kurman RJ, ed. 4th ed. Berlin (Germany): Springer Verlag 1995
- Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015;100:4588–94
- Stuenke CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975–4011
- Hully SB, Grady D. The WHI estrogen-alone trial-do things look any better? JAMA 2004;291:1769–71
- Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154–9
- Merz E, Miric-Tesanic D, Bahlmann F, et al. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol 1996;7:38–42
- Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000;3:199–211
- Santen RJ, Allred DC, Ardoin SP, et al. Endocrine Society.postmenopausal hormone therapy: an endocrine society scientific statement. J Clin Endocrinol Metab 2010;95:S7–S66